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Abstract: Epigenetic mechanisms influence molecular patterns important for the bone-metastatic
process, and here we highlight the role of WW-domain containing oxidoreductase (Wwox).
The tumor-suppressor Wwox lacks in almost all cancer types; the variable expression in osteosarcomas
is related to lung-metastasis formation, and exogenous Wwox destabilizes HIF-1α (subunit of
Hypoxia inducible Factor-1, HIF-1) affecting aerobic glycolysis. Our recent studies show critical
functions of Wwox present in 1833-osteotropic clone, in the corresponding xenograft model, and in
human bone metastasis from breast carcinoma. In hypoxic-bone metastatic cells, Wwox enhances
HIF-1α stabilization, phosphorylation, and nuclear translocation. Consistently, in bone-metastasis
specimens Wwox localizes in cytosolic/perinuclear area, while TAZ (transcriptional co-activator
with PDZ-binding motif) and HIF-1α co-localize in nuclei, playing specific regulatory mechanisms:
TAZ is a co-factor of HIF-1, and Wwox regulates HIF-1 activity by controlling HIF-1α. In vitro,
DNA methylation affects Wwox-protein synthesis; hypoxia decreases Wwox-protein level; hepatocyte
growth factor (HGF) phosphorylates Wwox driving its nuclear shuttle, and counteracting a Twist
program important for the epithelial phenotype and metastasis colonization. In agreement,
in 1833-xenograft mice under DNA-methyltransferase blockade with decitabine, Wwox increases
in nuclei/cytosol counteracting bone metastasis with prolongation of the survival. However,
Wwox seems relevant for the autophagic process which sustains metastasis, enhancing more Beclin-1
than p62 protein levels, and p62 accumulates under decitabine consistent with adaptability of
metastasis to therapy. In conclusion, Wwox methylation as a bone-metastasis therapeutic target
would depend on autophagy conditions, and epigenetic mechanisms regulating Wwox may influence
the phenotype of bone metastasis.
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1. Introduction
The formation of metastasis is a complex process, and the molecular events involved and their
genetic and epigenetic regulation vary depending on the primary tumor and the organotropism.
Recent studies deal with the role of proteins containing the WW structural module, critical for
protein-protein interaction, which play a multitude of functions through signaling networks. It is
intriguing the interaction of the co-factor Wwox (WW-domain containing oxidoreductase) with
Hippo pathway, which promotes cell death and differentiation counteracting cell proliferation [1].
Surprisingly, Hippo-signaling pathway seems also involved in tumorigenesis and metastasis in
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relation to the different patterns of Wwox [2,3]. In view of the plastic phenotype of metastases,
and the leading role played by epigenetic mechanisms, in the present review we dedicate a section
to the methylation-dependent functions of the tumor-suppressor Wwox, which is expressed in
bone metastases from breast carcinoma. Our newest observations are also shown and discussed
to give a better idea of the significance of Wwox in the autophagy process occurring in bone
metastases, and to update the knowledge of the cellular and molecular events triggered by DNA
methyltransferase blockade. Some of these points are highlighted taking into consideration that
epigenetic reprogramming is important for metastatic adaptability to the different microenvironments
encountered during the various steps from dissemination until bone colonization [4].
2. Lack of WWOX Gene Expression in Tumors, and Functional Effects of Exogenous Wwox
The human WWOX gene, encoding a 46 kDa protein, localizes on the chromosome 16q23.3–24.1
and consists of nine exons; at least eight alternative spliced mRNAs are known [5–11]. Putative
methylation sequences occur in the WWOX gene: 62 CpG sites span the WWOX promoter, exon 1,
and a small region of intron 1 [12]. As shown in Figure 1, in the full-length Wwox two WW domains
are present in the N-terminal region, and a nuclear localization signal is located between the first and
second WW domain. A short-chain alcohol dehydrogenase/reductase (ADH/SDR) is present in the
C-terminal domain, where a mitochondria-targeting sequence is mapped [13]. The domains for the
interaction of co-factors, which regulate Wwox activity, and the phosphorylation sites are indicated.
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Figure 1. Structure of WWOX gene and of the mature protein. The nine exons of the gene, and the 
domains for protein-protein interactions are indicated. WW, WW domain; NLS, nuclear localization 
sequence; ADH/SDR, short-chain alcohol dehydrogenase/reductase; MTS, mitochondrial targeting 
sequence; CpG sites, methylation sites; ITCH, E3 ubiquitin ligase; Runx2, Runt-related transcription 
factor 2; Hyal-2, hyaluronidase-2; GSK-3β, glycogen synthase kinase 3β. P, phospho. For Wwox 
protein, the amino acid position is indicated by the numbers. 
Wwox is involved in various patho-physiological conditions such as neural development, 
neural damage and neurodegeneration [13–18], bone metabolism [19,20], and osteoarthritis [21]. 
In agreement with Wwox function as tumor suppressor, WWOX gene spans a common fragile 
site FRA16D [5–11]. FRA16D, identified as one of the various sites of small homozygous deletions in 
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Wwox is involved in various patho-physiological conditions such as neural development, neural
damage and neurodegeneration [13–18], bone metabolism [19,20], and osteoarthritis [21].
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In agreement with Wwox function as tumor suppressor, WWOX gene spans a common fragile
site FRA16D [5–11]. FRA16D, identified as one of the various sites of small homozygous deletions
in cancer [22], belongs to the almost 200 fragile sites corresponding to regions of DNA instability in
different types of cancer. The perturbation of the function of the genes with common fragile sites
suggests their role in cancer cell biology [23]. WWOX does not seem to act as a highly penetrant
classical tumor suppressor [24], and low levels of Wwox, rather than complete absence of Wwox,
are often observed in tumors, indicating that the tumor suppressor function of Wwox does not
fit Knudson’s two hit hypothesis of tumorigenesis. Most intriguingly, protein levels of Wwox
are remarkably increased in the early stages of hyperplasia and cancerous progression of breast
and prostate cancer [25,26], and the significance might be that Wwox arrests cancer growth in the
preneoplastic stages, even if other scenarios cannot be excluded.
Reduced levels of full-length Wwox protein have been reported in multiple types of
cancer [11,27–29]. In particular, Wwox reduction or loss is observed in human osteosarcoma, but Wwox
expression is related to osteosarcoma aggressiveness and formation of lung metastases. Osteosarcoma
development seems to depend on destruction of the Wwox-p53 network in osteoprogenitors [30].
Evidence of individuals with low Wwox-protein levels, being more predisposed to the
development of lung cancer and gliomas, also supports a role for WWOX in tumorigenesis [31,32].
Aberrant WWOX transcripts are often observed in tumors with reduced levels of full-length
Wwox [27,33–35]. These transcripts mostly lack part, if not all, of the exons that encode its SDR
enzyme, and several of these transcripts are translated into truncated protein products lacking the
complete SDR enzyme, supporting oxidative stress [34,35].
Inactivation of WWOX gene participates in the progression of head and neck squamous cell
carcinoma (HNSCC). The downregulation of WWOX expression in advanced-stage tumor samples
of HNSCC is associated with methylation of the WWOX promoter region but not with miR-134
expression. The expression level of WWOX and the methylation of the promoter are inversely
correlated: 10 different alterations in the coding sequences and 18 different alterations in the non-coding
sequences of the WWOX gene in HNSCC tumor samples are reported. Thus, WWOX gene can
be inactivated epigenetically by promoter methylation, or functionally by mutations affecting the
sequences coding for the enzymatic domain of the gene [36].
Altered metabolism is now recognized as one of the hallmarks of cancer cells, due to mutations
of enzymes of the tricarboxylic acid cycle and of the mitochondrial respiratory chain [37]. A novel
functional contribution of Wwox in moderating the mitochondria-mediated pathway, related to the
aerobic metabolism, depends upon its SDR enzyme function [38].
Moreover, the loss of Wwox seems to contribute to the metabolic reprogramming of cells that
accompanies tumorigenesis (Figure 2).
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Hypoxia inducible factor-1 (HIF-1) is the master regulator of oxygen homeostasis and of aerobic
glycolysis in tumors, and HIF-1α is the inducible subunit [39]. As shown by Abu-Remaileh and
Aqeilan, exogenous Wwox decreases HIF-1α protein level both in vitro and in vivo; WWOX knockout
mice exhibit enhanced levels of serum lactic acid [20]. The mechanisms proposed are the degradation
of HIF-1α via prolyl hydroxylase control, and the suppression of HIF-1 transcriptional function [20].
The loss of WWOX is responsible for the activation of the glycolysis in mouse embryonic fibroblasts
(MEF) from knockout (K.O.) embryos, compared with fibroblasts from WWOX-wild type embryos [40].
Notwithstanding hypoxia downregulates Wwox in different cell types as in 1833-bone metastatic cells,
derived from MDA-MB231 breast carcinoma cells [20,41], only in 1833 cells exogenous Wwox stabilizes
HIF-1α: the latter effect is more pronounced under moderate hypoxia. The underlying mechanism
has been studied by us [41] (see the paragraph on Wwox in bone metastasis), and might explain some
aspects of the control of HIF-1-dependent gene pattern in skeleton metastasis expressing Wwox.
In breast carcinoma cells, Wwox antagonizes the function of YAP (Yes-associated protein),
regulating in nuclei the transcriptional activity of tyrosine kinase receptors; overexpression of Wwox
suppresses the activity of the transcription factors p73, AP2, Erb4, c-Jun, and Met, sequestering them in
the cytosol [42,43]. YAP is a WW-domain containing regulatory protein, and we deepen the significance
using two breast carcinoma cell lines (i.e., the invasive MDA-MB231 and the non-invasive MCF-7
cells). Only in MDA-MB231 cells, Met receptor fragments (Met-CTF) are present in nuclei, and they
play a transactivating function: in these cells Wwox is lacking, and in nuclei YAP- phosphorylated by
Akt- intervenes as a co-factor in Met-CTF activity important for spontaneous invasiveness. Exogenous
Wwox overexpression causes Met loss of function, due to the impairment of Met-CTF nuclear
localization [42].
Other functions of Wwox are related to signal transduction pathways. In colon carcinoma cells
HCT116 deficient in TGFβRII, TGFβ1 binds cell surface hyaluronidase Hyal-2, followed by a rapid
recruitment of Wwox. The resulting Wwox/Hyal-2 complex recruits Smad4, relocates to the nuclei
enhancing Smad promoter activation, important for the control of gene transcription [2]. Ezrin,
a member of the membrane-cytoskeleton linker family, is implicated in a variety of cellular dynamics
such as determination of cell shape, adhesion, motility, and survival; ezrin interacts with Wwox
determining its apical localization, which is important for proton pump H,K-ATPase recruitment to
apical membrane during the gastric-parietal cell activation [44].
3. The Hippo Pathway in Tumorigenesis
3.1. YAP and TAZ Function as Transcriptional Co-Activators
YAP and TAZ (transcriptional co-activator with PDZ-binding motif, and one WW domain)
are proteins of the core of Hippo pathway, and regulate gene transcription critical for embryonic
development and tumorigenesis by signal transduction from the cytoplasm to the nucleus [45].
YAP and TAZ do not contain intrinsic DNA-binding domains, but they may interact with transcription
factors targeting specific gene promoters [3]. A further complexity is given by the inhibition of
these core proteins downstream of the Hippo pathway via LATS1/2 phosphorylation, activated by
MST1/2 [46,47].
YAP1 contributes to the KRas-dependent transformed phenotype, and it drives proliferation
by acting as cofactor for TEA Domain (TEAD) transcriptional regulator; when TEAD association is
disrupted, YAP1 activity is lost [48]. The ablation of epithelial integrity, together with subsequent
YAP1 nuclear localization, allows transcriptional activation of β-catenin/TEX-YAP/TEAD target genes,
including Myc, responsible for the invasive phenotype [49].
3.2. Aberrant Signaling in Tumors
In model systems, genetic ablation of core Hippo pathway components leads to increased
tumorigenesis [48]. Published data on humans report either mutations of Guanine nucleotide-binding
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protein Gq subunit α (GNAQ), as in uveal melanoma, or inactivation of NF2/merlin, as in the
tumor-prone neurofibromatosis syndrome. These mutations may hamper the inhibitory signal of
LATS1 permitting YAP1 activation: the latter occurs independently of Hippo kinase MST itself.
Similarly, molecular mechanisms regulated by stroma and genetic instability are triggered independent
of LATS1/2 phosphorylation activated by MST1/2 [48].
Proteomic studies identify that the main direct activators of MST kinases are SAV1 and
RASSFs [50]. Although infrequently mutated in cancers [51], germline and epigenetic alterations
involve particularly RASSF1A, accelerating tumor onset and increasing tumorigenicity [52,53]. Distinct
RASSF1 isoforms have opposite functions, providing biomarkers for YAP1 activation, and explaining
the correlations of RASSF1 methylation with invasive growth in humans.
Interesting advancement regards the identification of numerous upstream components of the
Hippo pathway, such as cell polarity, mechanotransduction, and G-protein coupled receptor signaling.
However, in tumors, the effect of deranged upstream components on Hippo pathway function is
scarcely known. Physical attachment of normal cells to extracellular matrix is essential for survival and
growth, due to the YAP nuclear localization, and the activation of Rho-GTPases or of the FAK-Src-PI3K
pathway [54,55]. Rho-GTPases and the actin cytoskeleton play an essential role in the regulation
of YAP and TAZ by mechanotransduction. Tensive forces couple to the cytoskeleton to integrate
and transmit upstream signals to the core Hippo signaling cascade [1], and the mechanical strain
suppresses YAP phosphorylation promoting YAP nuclear translocation by inactivating LATS1/2 in a
JNK-dependent manner [56]. Thus, the Hippo pathway not only intervenes in the growth inhibitory
signal due to cell-cell contact at high cell density [47], but it also permits to overcome the physical
restrictions due to extracellular mechanical cues, favoring growth and development. Nuclear YAP
or TAZ seems to influence TGFβ signaling towards an aggressive phenotype. In fact, YAP/TAZ may
hamper tumor-suppressive events, recruiting NCoR/HDAC3 chromatin-remodeling complex to gene
promoters [3].
Exciting findings indicate that epigenetic mechanisms might deregulate the tumor suppressive
Hippo pathway and the signaling downstream implicated in tumorigenesis.
4. Wwox Influences the Gene Pattern of Human Bone Metastasis from Breast Carcinoma
Recently, we reported unexpected findings that Wwox tumor suppressor is elevated in specimens
of human bone metastasis. While being almost absent in primary invasive ductal breast carcinoma,
the adjacent mammary tissue shows Wwox signal. In human bone metastasis, Wwox localizes at
cytosolic-perinuclear and at nuclear levels [41,57,58]. Consistently, endogenous Wwox expression is
remarkably higher in 1833 bone-metastatic clone than in invasive MDA-MB231 breast carcinoma cells,
and it is similarly elevated in non-invasive MCF-7 breast carcinoma cells (Figure 3A).
These data stimulate the studies of Wwox function and regulation in bone metastases. Recent
findings indicate the association of WWOX gene polymorphism with the risk of metastasis from
osteosarcoma, that is known to metastasize in the brain and lungs [59]. In any case, Wwox expression
and function in metastases other than the osseous one are practically unknown due to the difficulties
to obtain human samples and to prepare animal models.
The adaptability of the disseminated cancer cells to the different microenvironments encountered
during the various steps of the metastatic process depends on the dynamic phenotype, which is
regulated principally by epigenetic mechanisms and hypoxia [39,60–62]. Importantly, in 1833 cells
Wwox expression varies with DNA-methylation state and hypoxic conditions [41,57]. These points
deserve discussion, and clarify the significance of Wwox in bone metastases.
First, the endogenous level of Wwox protein in 1833 cells is regulated by DNA methyltransferases,
and long-term exposure to the inhibitor 5-azacytidine causes Wwox downregulation [57].
The 5-azacytidine molecule is incorporated into newly synthesized DNA after conversion to
5-aza-2′-deoxycytidine [63]. Of note, the treatment of 1833-xenograft mice with the inhibitor of
DNA methyltransferases 5-aza-2′-deoxycytidine (decitabine), prolongs mouse survival and increases
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Wwox expression both in cytosol and nuclei. Oppositely, hepatocyte growth factor (HGF)/Met
receptor, one of the principal bone-metastatic regulatory axis, is downregulated [64]. An explanation
might be that microenvironmental stimuli of bone metastases, such as HGF, influence Wwox level,
phosphorylation and function. HGF controls a Twist program for transient mesenchymal-epithelial
transition, which is important for colonization, via E-cadherin expression and vimentin/MMP2
downregulation, and probably also for osteoclast activity [58]. HGF permits Twist access into the
nuclei in a phosphorylated form, while Wwox phosphorylated exchanges with Twist, which shuttles in
the cytosol in unphosphorylated form ending the program. A TGFβ1 signaling is activated downstream
HGF, contributing to the plastic phenotype of bone metastasis and to the colonization associated with
osteolysis [58].
Altogether, to devise therapies targeting the epithelial phenotype, or the reverse mesenchymal
phenotype in a time-dependent manner, the situation of biological and physical (hypoxia) stimuli of
the microenvironment has to be considered, because they might co-operate influencing Wwox function
and also the efficacy of DNA methyltransferase blockade.
Secondly, to clarify the significance of elevated Wwox expression in bone metastasis, Maroni et al.
reproduce this condition through the ectopic expression of Wwox [41]. In 1833 and MDA-MB231 cells
transfected with WWOX-expression vector, invasiveness through Matrigel increases and decreases,
respectively, even if Wwox protein accumulates in both the cell lines: this finding indicates different
effects of exogenous Wwox on the gene patterns for the motile phenotype depending on the cell
type [57]. After enhancement of Wwox-mediated migration through Matrigel, the 1833 cells undertake
contacts consistent with E-cadherin expression [57]. A key mechanism for modulating cell-cell adhesion
strength is the adjustment of the amount of E-cadherin [65], and Wwox influencing E-cadherin
expression contributes to mesenchymal-epithelial transition and colonization of bone metastasis from
breast carcinoma [58].
The re-expression of E-cadherin in bone metastasis contributes to aberrant homotypic/heterotypic
cell adhesion, motility and transduction signaling [66], and Wwox is likely to influence E-cadherin
intracellular localization and function. E-cadherin-containing surface structures affect adhesion and
colonization of bone metastasis [67]: redistribution of COOH-E-cadherin fragment in nuclei seems to
favor invasion [68]. Notably, in humans E-cadherin and Wwox are expressed in bone metastasis but
not in breast carcinoma, while HIF-1α and TAZ are localized principally in nuclei of metastasis and
throughout breast carcinoma cells [41]: TAZ is a HIF-1 co-factor in bone metastases [69].
Importantly, we show a molecular mechanism typical of skeletal metastasis, which implicates
Wwox as a player in the HIF-1α-HDM2 regulatory loop, necessary for the dynamic regulation of
HIF-1α amount and HIF-1 activity. Hypoxia is additive with Wwox, remarkably enhancing HIF-1α
nuclear shuttle and accumulation due to lengthening of the half-life of HIF-1α protein. By interacting
with HDM2 and sequestering the E3-ubiquitin ligase, Wwox is likely to prevent HIF-1α degradation
under mild hypoxia favoring HIF-1 activity [41]. The effect of exogenous Wwox on the metabolism
of metastatic cells via aerobic glycolysis has not been investigated. In primary breast carcinoma with
low or null Wwox, HIF-1α levels are controlled through stabilization dependent on hypoxia and
oncogenes [39].
In contrast to oxidative stress and energy stress, hypoxia causes YAP and TAZ activation by
inhibiting LATS through the SIAH2-E3 ubiquitin ligase, which destabilizes LATS2 [47]. In 1833
clone, but not in parental MDA-MB231 cells, hypoxia induces E-cadherin through HIF-1 and PPARγ
activities [41].
Thirdly, the intracellular localization of Wwox is important for the function, and may vary
depending upon the status of cell differentiation and the types of cells tested [6]. In normal
keratinocytes Wwox frequently localizes in the perinuclear area, and when they start undergoing
cornification it accumulates in the nucleus [6]. Numerous biological and stress stimuli induce
re-location of Wwox to the nuclei. In response to TNF-α, TGF-β, staurosporine, etoposide,
ultraviolet irradiation, complement C1q, and sex steroid hormones (androgen and estrogen),
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Wwox phosphorylation at Tyr33 occurs in many cultured cell lines: phosphorylated or activated
Wwox translocates to the mitochondria and nuclei [25,70–73].Int. J. Mol. Sci. 2017, 18, 75 7 of 12 
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complet ly clarified. Two key playe f t t agy are Beclin-1 index of the autophagic flux,
being involved in isolation/ e brane initiation, and p62-scaffold protein, which may be substrate
of autophagy or adapter regulating survival pathways involving NF-κB activity [75,76]. As shown
in Figure 3B, the transfection of WWOX expression vector increased strongly Beclin-1 and less p62
protein levels in 1833 cells (quantification of the data is included in the graphic). Ectopic Wwox,
that in vivo might derive from microenvironment supportive cells of bone metastasis, is likely to
influence the initial autophagosome formation and the following autolysosome function where Beclin-1
and p62 are critically implicated. One of the two events, i.e., autophagy activation or block of p62
degradation, might be sufficient to cope with the environment or cell stress conditions in bone
metastasis. It can be hypothesized that Wwox per se influences p62 induction notwithstanding
autophagy flux: p62 is affected by oxidative stress and Wwox seems to cause the formation of
reactive oxygen species [38,76]. Under decitabine, the p62 degradation was prevented probably due
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to the impairment of the autophagic process being Beclin-1 unchanged and Wwox downregulated.
As a consequence of autophagy failure, the metastatic cells are under stressful conditions which
induced p62, because of the hampering of energy supply and removal of damaged organelles. Further
studies are needed to clarify the significance of p62 in bone metastasis under therapy targeting
DNA methyltransferases.
The data on autophagy contribute to clarifying the effect of decitabine in mice bearing bone
metastases from breast carcinoma. The efficacy of decitabine, a chemotherapic drug for various
kinds of primary tumors never tested to fight bone metastases, might be strongly influenced by
the microenvironment biological stimuli acting on the molecular mediators like Wwox, and by the
autophagy conditions.
5. Conclusions
Wwox’s role in cancer progression is one of the intensely debated concepts, because of its double
nature in primary tumor growth and metastatic process, and its relation with HIF-1α expression/HIF-1
activity. Wwox may influence the gene pattern underlying the phenotype of bone metastasis:
Wwox counteracts YAP function, positive for HGF/Met receptor signaling, and activates HIF-1 with
upregulation of E-cadherin; finally, phosphoWwox downregulates Twist transactivation, reverting the
epithelial phenotype important for colonization. Altogether, Wwox seems to play key functions in
bone metastasis from breast carcinoma (Figure 4).
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Figure . Wwox plays various functions in bone metastasis, related to gene expre sion for
esenchymal epithelial transition and autophagy. EMT, epithelial-mesenchymal transition; MET,
esenchy al-epithelial tra sitio ;
Wwox drives the switch towards an epithelial phenotype due to E-cadherin expression, critical for
osteoblastic niche formation and colonization, and the autophagy triggering which might be implicated
in survival of metastatic cells engrafted in the bone. We suggest the importance for metastasis therapy
of Wwox involvement in the nuclear shift (i) of HIF-1α subunit-contributing to HIF-1 activation under
hypoxia; and (ii) of Twist under HGF: the phosphorylation and stabilization of these transcription
factors lead to the expression of genes critical for the bone-metastatic process. The p62 saved from
degradation because of Wwox-dependent interference in the autophagosome sealing and lipidation
with LC3II, might activate NF-κB. The latter transcription factor controls a gene pattern (HIF-1α, COX2,
ornithine decarboxylase) important for metastasis growth [41,77,78] and apoptosis resistance [79].
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Wwox is regulated by methylation, and the chemotherapic drug decitabine might be useful to affect
bone metastasis colonization, preventing Met receptor fragment and Twist access to nuclei, but the
efficacy might dependent on autophagy conditions.
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YAP Yes-associated protein
TAZ Transcriptional co-activator with PDZ-binding motif
Wwox WW-domain containing oxidoreductase
TEAD TEA Domain
ADH/SDR Short-chain alcohol dehydrogenase/reductase
HIF-1 Hypoxia inducible factor-1
Met-CTF Met receptor fragments
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